Skip to content
Paragon Biosciences LLC
  • About Us
  • Our Approach
  • Portfolio
  • Leadership
  • Careers
  • Contact Us
  • News Room

Uncategorized

2 items

  • June 11, 2026

    Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

    Agreement highlights Paragon’s ability to build companies around [...]

  • May 26, 2026

    JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome

    Phase 3 data show delayed time to relapse [...]

© 2026 Paragon Biosciences LLC | Privacy Policy | Terms of Use

330 N Wabash Avenue, Suite 3500, Chicago, IL 60611 |

© 2026 Paragon Biosciences LLC | Privacy Policy | Terms of Use

330 N Wabash Avenue, Suite 3500, Chicago, IL 60611

© 2026 Paragon Biosciences LLC
Privacy Policy | Terms of Use

330 N Wabash Avenue, Suite 3500
Chicago, IL 60611

Page load link
Go to Top